nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—Peripheral ischaemia—Varenicline—nicotine dependence	0.0504	0.0767	CcSEcCtD
Dihydroergotamine—Parosmia—Varenicline—nicotine dependence	0.0283	0.0432	CcSEcCtD
Dihydroergotamine—Ergoloid mesylate—DRD2—nicotine dependence	0.0231	0.566	CrCbGaD
Dihydroergotamine—Disturbance in attention—Varenicline—nicotine dependence	0.0212	0.0323	CcSEcCtD
Dihydroergotamine—Influenza like illness—Varenicline—nicotine dependence	0.0179	0.0272	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Varenicline—nicotine dependence	0.0179	0.0272	CcSEcCtD
Dihydroergotamine—Photophobia—Varenicline—nicotine dependence	0.0173	0.0263	CcSEcCtD
Dihydroergotamine—Mental disability—Varenicline—nicotine dependence	0.016	0.0243	CcSEcCtD
Dihydroergotamine—Euphoric mood—Varenicline—nicotine dependence	0.0158	0.0241	CcSEcCtD
Dihydroergotamine—Eye pain—Varenicline—nicotine dependence	0.0148	0.0225	CcSEcCtD
Dihydroergotamine—Injury—Varenicline—nicotine dependence	0.0145	0.0221	CcSEcCtD
Dihydroergotamine—Hot flush—Varenicline—nicotine dependence	0.0143	0.0217	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Varenicline—nicotine dependence	0.0141	0.0215	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Varenicline—nicotine dependence	0.0136	0.0207	CcSEcCtD
Dihydroergotamine—Migraine—Varenicline—nicotine dependence	0.0131	0.02	CcSEcCtD
Dihydroergotamine—Cramp muscle—Varenicline—nicotine dependence	0.012	0.0183	CcSEcCtD
Dihydroergotamine—Dysphagia—Varenicline—nicotine dependence	0.0115	0.0176	CcSEcCtD
Dihydroergotamine—Angina pectoris—Varenicline—nicotine dependence	0.0112	0.0171	CcSEcCtD
Dihydroergotamine—Bronchitis—Varenicline—nicotine dependence	0.0111	0.0169	CcSEcCtD
Dihydroergotamine—Pollakiuria—Varenicline—nicotine dependence	0.0107	0.0162	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Varenicline—nicotine dependence	0.0101	0.0154	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Varenicline—nicotine dependence	0.0101	0.0153	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Varenicline—nicotine dependence	0.01	0.0152	CcSEcCtD
Dihydroergotamine—Epistaxis—Varenicline—nicotine dependence	0.0097	0.0148	CcSEcCtD
Dihydroergotamine—Sinusitis—Varenicline—nicotine dependence	0.00965	0.0147	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Varenicline—nicotine dependence	0.00918	0.014	CcSEcCtD
Dihydroergotamine—Ergotamine—DRD2—nicotine dependence	0.00904	0.221	CrCbGaD
Dihydroergotamine—Visual impairment—Varenicline—nicotine dependence	0.0089	0.0135	CcSEcCtD
Dihydroergotamine—Bromocriptine—DRD2—nicotine dependence	0.00871	0.213	CrCbGaD
Dihydroergotamine—Tinnitus—Varenicline—nicotine dependence	0.00861	0.0131	CcSEcCtD
Dihydroergotamine—Chills—Varenicline—nicotine dependence	0.00828	0.0126	CcSEcCtD
Dihydroergotamine—HTR1B—cardiovascular system—nicotine dependence	0.00817	0.101	CbGeAlD
Dihydroergotamine—HTR1D—cardiovascular system—nicotine dependence	0.00791	0.0978	CbGeAlD
Dihydroergotamine—Muscle spasms—Varenicline—nicotine dependence	0.00773	0.0118	CcSEcCtD
Dihydroergotamine—Tremor—Varenicline—nicotine dependence	0.00753	0.0115	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Varenicline—nicotine dependence	0.00746	0.0114	CcSEcCtD
Dihydroergotamine—Agitation—Varenicline—nicotine dependence	0.00738	0.0112	CcSEcCtD
Dihydroergotamine—HTR2B—cardiovascular system—nicotine dependence	0.00736	0.091	CbGeAlD
Dihydroergotamine—Malaise—Varenicline—nicotine dependence	0.00725	0.011	CcSEcCtD
Dihydroergotamine—Vertigo—Varenicline—nicotine dependence	0.00722	0.011	CcSEcCtD
Dihydroergotamine—Palpitations—Varenicline—nicotine dependence	0.0071	0.0108	CcSEcCtD
Dihydroergotamine—Hypertension—Varenicline—nicotine dependence	0.00694	0.0106	CcSEcCtD
Dihydroergotamine—Arthralgia—Varenicline—nicotine dependence	0.00684	0.0104	CcSEcCtD
Dihydroergotamine—Myalgia—Varenicline—nicotine dependence	0.00684	0.0104	CcSEcCtD
Dihydroergotamine—Anxiety—Varenicline—nicotine dependence	0.00682	0.0104	CcSEcCtD
Dihydroergotamine—Discomfort—Varenicline—nicotine dependence	0.00676	0.0103	CcSEcCtD
Dihydroergotamine—Dry mouth—Varenicline—nicotine dependence	0.00669	0.0102	CcSEcCtD
Dihydroergotamine—HTR6—brain—nicotine dependence	0.00666	0.0823	CbGeAlD
Dihydroergotamine—HTR6—Monoamine GPCRs—DRD2—nicotine dependence	0.00663	0.0299	CbGpPWpGaD
Dihydroergotamine—HTR1A—cardiovascular system—nicotine dependence	0.0066	0.0815	CbGeAlD
Dihydroergotamine—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00658	0.0297	CbGpPWpGaD
Dihydroergotamine—Oedema—Varenicline—nicotine dependence	0.00656	0.00999	CcSEcCtD
Dihydroergotamine—Shock—Varenicline—nicotine dependence	0.00645	0.00983	CcSEcCtD
Dihydroergotamine—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00644	0.0291	CbGpPWpGaD
Dihydroergotamine—Tachycardia—Varenicline—nicotine dependence	0.0064	0.00975	CcSEcCtD
Dihydroergotamine—HTR1B—midbrain—nicotine dependence	0.00638	0.0789	CbGeAlD
Dihydroergotamine—Hyperhidrosis—Varenicline—nicotine dependence	0.00634	0.00965	CcSEcCtD
Dihydroergotamine—Anorexia—Varenicline—nicotine dependence	0.00625	0.00952	CcSEcCtD
Dihydroergotamine—HTR1D—midbrain—nicotine dependence	0.00618	0.0764	CbGeAlD
Dihydroergotamine—Hypotension—Varenicline—nicotine dependence	0.00613	0.00933	CcSEcCtD
Dihydroergotamine—HTR2B—Monoamine GPCRs—DRD2—nicotine dependence	0.00605	0.0273	CbGpPWpGaD
Dihydroergotamine—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00598	0.0091	CcSEcCtD
Dihydroergotamine—Insomnia—Varenicline—nicotine dependence	0.00593	0.00903	CcSEcCtD
Dihydroergotamine—Dyspnoea—Varenicline—nicotine dependence	0.00585	0.0089	CcSEcCtD
Dihydroergotamine—Somnolence—Varenicline—nicotine dependence	0.00583	0.00888	CcSEcCtD
Dihydroergotamine—Dyspepsia—Varenicline—nicotine dependence	0.00577	0.00879	CcSEcCtD
Dihydroergotamine—Decreased appetite—Varenicline—nicotine dependence	0.0057	0.00868	CcSEcCtD
Dihydroergotamine—Fatigue—Varenicline—nicotine dependence	0.00565	0.00861	CcSEcCtD
Dihydroergotamine—Pain—Varenicline—nicotine dependence	0.00561	0.00854	CcSEcCtD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00557	0.0252	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00553	0.025	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00542	0.0244	CbGpPWpGaD
Dihydroergotamine—Feeling abnormal—Varenicline—nicotine dependence	0.0054	0.00823	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00536	0.00817	CcSEcCtD
Dihydroergotamine—Urticaria—Varenicline—nicotine dependence	0.00521	0.00793	CcSEcCtD
Dihydroergotamine—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00519	0.0234	CbGpPWpGaD
Dihydroergotamine—Abdominal pain—Varenicline—nicotine dependence	0.00518	0.00789	CcSEcCtD
Dihydroergotamine—Body temperature increased—Varenicline—nicotine dependence	0.00518	0.00789	CcSEcCtD
Dihydroergotamine—HTR1A—midbrain—nicotine dependence	0.00515	0.0637	CbGeAlD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00509	0.023	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.00491	0.0222	CbGpPWpGaD
Dihydroergotamine—Hypersensitivity—Varenicline—nicotine dependence	0.00483	0.00736	CcSEcCtD
Dihydroergotamine—Asthenia—Varenicline—nicotine dependence	0.00471	0.00717	CcSEcCtD
Dihydroergotamine—Pruritus—Varenicline—nicotine dependence	0.00464	0.00707	CcSEcCtD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00449	0.0203	CbGpPWpGaD
Dihydroergotamine—Diarrhoea—Varenicline—nicotine dependence	0.00449	0.00683	CcSEcCtD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.0044	0.0198	CbGpPWpGaD
Dihydroergotamine—Dizziness—Varenicline—nicotine dependence	0.00434	0.0066	CcSEcCtD
Dihydroergotamine—Vomiting—Varenicline—nicotine dependence	0.00417	0.00635	CcSEcCtD
Dihydroergotamine—Rash—Varenicline—nicotine dependence	0.00414	0.0063	CcSEcCtD
Dihydroergotamine—Dermatitis—Varenicline—nicotine dependence	0.00413	0.00629	CcSEcCtD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00413	0.0186	CbGpPWpGaD
Dihydroergotamine—Headache—Varenicline—nicotine dependence	0.00411	0.00626	CcSEcCtD
Dihydroergotamine—HTR1B—brain—nicotine dependence	0.00401	0.0496	CbGeAlD
Dihydroergotamine—Nausea—Varenicline—nicotine dependence	0.0039	0.00593	CcSEcCtD
Dihydroergotamine—HTR1D—brain—nicotine dependence	0.00388	0.048	CbGeAlD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00386	0.0174	CbGpPWpGaD
Dihydroergotamine—HTR2B—brain—nicotine dependence	0.00361	0.0447	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—nicotine dependence	0.00361	0.0446	CbGeAlD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00335	0.0151	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00324	0.0146	CbGpPWpGaD
Dihydroergotamine—HTR1A—brain—nicotine dependence	0.00324	0.04	CbGeAlD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00287	0.013	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—TAS2R16—nicotine dependence	0.00274	0.0124	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00272	0.0123	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00266	0.012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00263	0.0119	CbGpPWpGaD
Dihydroergotamine—ABCB1—cardiovascular system—nicotine dependence	0.00258	0.0318	CbGeAlD
Dihydroergotamine—HTR2B—GPCR ligand binding—TAS2R16—nicotine dependence	0.0025	0.0113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—brain—nicotine dependence	0.00227	0.028	CbGeAlD
Dihydroergotamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00215	0.00972	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00213	0.00959	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00203	0.00915	CbGpPWpGaD
Dihydroergotamine—ABCB1—midbrain—nicotine dependence	0.00201	0.0249	CbGeAlD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00192	0.00865	CbGpPWpGaD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00189	0.00854	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00185	0.00836	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00177	0.00799	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00176	0.00793	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00175	0.00788	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00174	0.00785	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00172	0.00776	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00162	0.00729	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00159	0.00719	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00155	0.00699	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00154	0.00693	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00152	0.00684	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0015	0.00679	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0015	0.00679	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00147	0.00665	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00141	0.00638	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00141	0.00637	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—TAS2R16—nicotine dependence	0.00141	0.00634	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00139	0.0063	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00138	0.00625	CbGpPWpGaD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.00137	0.00618	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00137	0.00617	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00134	0.00605	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00131	0.00591	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00128	0.00579	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00128	0.00578	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00127	0.00573	CbGpPWpGaD
Dihydroergotamine—ABCB1—brain—nicotine dependence	0.00126	0.0156	CbGeAlD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00124	0.00561	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—FGD1—nicotine dependence	0.00121	0.00548	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.00121	0.00544	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00118	0.00533	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00117	0.00527	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—OPRM1—nicotine dependence	0.00115	0.00521	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.00115	0.00517	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00115	0.00517	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00112	0.00507	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.00112	0.00506	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00111	0.00501	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—FGD1—nicotine dependence	0.00111	0.005	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—FGD1—nicotine dependence	0.0011	0.00498	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.0011	0.00495	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.00109	0.00494	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00109	0.00491	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.00107	0.00484	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00107	0.00481	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—OPRM1—nicotine dependence	0.00105	0.00476	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00104	0.0047	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00103	0.00465	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.00102	0.00461	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—FGD1—nicotine dependence	0.00101	0.00454	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.001	0.00452	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000984	0.00444	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000947	0.00428	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000927	0.00419	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000915	0.00413	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0009	0.00407	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000899	0.00406	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000882	0.00398	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000855	0.00386	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—DRD2—nicotine dependence	0.000835	0.00377	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TAS2R16—nicotine dependence	0.00083	0.00375	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000828	0.00374	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000824	0.00372	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000818	0.00369	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000816	0.00369	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000811	0.00366	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000811	0.00366	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000807	0.00364	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000802	0.00362	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—DRD2—nicotine dependence	0.000762	0.00344	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TAS2R16—nicotine dependence	0.000758	0.00342	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000744	0.00336	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000707	0.00319	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000672	0.00303	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—OPRM1—nicotine dependence	0.000652	0.00295	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGD1—nicotine dependence	0.000652	0.00294	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000647	0.00292	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000647	0.00292	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—FGD1—nicotine dependence	0.000642	0.0029	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000638	0.00288	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000634	0.00286	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.000633	0.00286	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	0.000618	0.00279	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000615	0.00277	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000596	0.00269	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGD1—nicotine dependence	0.000595	0.00268	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—OPRM1—nicotine dependence	0.000592	0.00267	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.000588	0.00265	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000576	0.0026	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKR1B10—nicotine dependence	0.000575	0.0026	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000571	0.00258	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000559	0.00252	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00055	0.00248	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—OPRM1—nicotine dependence	0.000541	0.00244	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKR1B10—nicotine dependence	0.000525	0.00237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD2—nicotine dependence	0.000486	0.00219	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000483	0.00218	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000483	0.00218	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGD1—nicotine dependence	0.000482	0.00218	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD2—nicotine dependence	0.000472	0.00213	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000468	0.00211	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000458	0.00207	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000439	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD2—nicotine dependence	0.000431	0.00194	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD2—nicotine dependence	0.000428	0.00193	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000426	0.00192	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.000425	0.00192	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000416	0.00188	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—WASF2—nicotine dependence	0.000405	0.00183	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000402	0.00182	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.000394	0.00178	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD2—nicotine dependence	0.000391	0.00177	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—WASF1—nicotine dependence	0.000389	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.000386	0.00174	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.00038	0.00171	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGD1—nicotine dependence	0.000379	0.00171	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.000378	0.00171	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP2A7—nicotine dependence	0.000372	0.00168	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WASF2—nicotine dependence	0.00037	0.00167	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WASF1—nicotine dependence	0.000355	0.0016	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—OPRM1—nicotine dependence	0.00035	0.00158	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000349	0.00158	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000347	0.00157	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000345	0.00156	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.00034	0.00154	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000335	0.00151	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—OPRM1—nicotine dependence	0.000319	0.00144	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	0.000317	0.00143	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WASF2—nicotine dependence	0.0003	0.00135	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WASF1—nicotine dependence	0.000288	0.0013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000274	0.00124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	0.000259	0.00117	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000257	0.00116	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD2—nicotine dependence	0.000253	0.00114	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.000251	0.00113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD2—nicotine dependence	0.000249	0.00113	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.000246	0.00111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WASF2—nicotine dependence	0.000236	0.00106	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD2—nicotine dependence	0.000231	0.00104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WASF1—nicotine dependence	0.000226	0.00102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—OPRM1—nicotine dependence	0.000204	0.000919	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD2—nicotine dependence	0.000187	0.000846	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000159	0.000716	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD2—nicotine dependence	0.000147	0.000665	CbGpPWpGaD
